Cita APA (7a ed.)
(2002). Arixtra: Four weeks of Tx significantly reduces DVT/PE risk in hip fracture patients. Formulary, 37(10), 505-506.
Cita Chicago Style (17a ed.)
"Arixtra: Four Weeks of Tx Significantly Reduces DVT/PE Risk in Hip Fracture Patients." Formulary 37, no. 10 (2002): 505-506.
Cita MLA (9a ed.)
"Arixtra: Four Weeks of Tx Significantly Reduces DVT/PE Risk in Hip Fracture Patients." Formulary, vol. 37, no. 10, 2002, pp. 505-506.
Precaución: Estas citas no son 100% exactas.